查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951775

药物动力学服务市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终用户、阶段划分

Pharmacokinetics Services Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Stage
出版日期: | 出版商: Global Insight Services | 英文 375 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，药物动力学服务市场规模将从2024年的16亿美元成长至29亿美元，复合年增长率约为6%。药物动力学服务市场涵盖评估药物吸收、分布、代谢和排泄的分析和咨询服务。这些服务在药物研发中至关重要，透过提供药物交互作用和剂量优化等重要数据，确保药物的安全性和有效性。製药业研发投入的不断增加以及药物製剂复杂性的日益提高，正在推动市场成长，同时也凸显了对先进分析技术和法规遵从性的需求。

受药物研发和个人化医疗发展趋势的推动，药物动力学服务市场正经历强劲成长。药物研发领域成长最为显着，这主要得益于早期临床试验中对精准药物动力学分析需求的持续成长。在该领域，确保药物浓度准确测量的生物分析服务至关重要。临床药物动力学子领域也备受关注，因为它能够为剂量优化和疗效评估提供重要资讯。成长第二快的领域是委外研发机构（CRO），由于其专业技术和成本效益，CRO 的应用日益广泛。在 CRO 中，小分子药物动力学服务的重要性日益凸显，这得益于其成熟的调查方法和对学名药生产的需求。此外，生物製药动力学服务也正在崛起，成为关键领域，反映了市场转型为生物製药研发的转型。人工智慧和机器学习等先进技术的融合正在提升数据分析能力，进一步推动市场扩张。

市场区隔
类型 吸收、分布、代谢和排泄
产品 软体、分析设备和耗材
服务 咨询、生物分析、资料管理、临床试验
科技 液相层析质谱联用（LC-MS）、高效液相层析（HPLC）、气相层析质谱联用（GC
应用 药物研发、临床试验、毒性测试、生物等效性测试
最终用户 製药公司、生技公司、受託研究机构、学术机构
步 非临床试验、I期临床试验、II期临床试验、III期临床试验、上市后监测

随着新兴企业挑战现有企业，药物动力学服务市场的市场份额正经历动态变化。定价策略也不断演变，反映出市场对个人化医疗和先进药物研发日益增长的需求。近期推出的产品强调创新技术和全面的服务，以满足不同客户群的需求。由于技术应用和医疗基础设施的改善，主要地区的成长轨迹并不均衡。随着企业寻求竞争优势，策略联盟和伙伴关係变得日益重要。药物动力学服务市场的竞争日益激烈，各企业纷纷以业界领导企业为标桿，以提升服务品质。监管的影响显着，北美和欧洲的严格指导方针塑造了营运标准。亚太地区的新兴市场正迅速适应全球法规结构，这为其提供了新的成长途径。市场分析显示，一种趋势正在向整合药物动力学和动态的综合服务模式发展，该模式提供全面的药物研发解决方案。此外，生物分析技术的进步和个人化医疗的兴起进一步丰富了市场格局，预示着未来将保持强劲成长。

主要趋势和驱动因素：

受多项关键趋势和驱动因素的影响，药物动力学服务市场正经历强劲成长。其中一个显着趋势是，个人化医疗的需求日益增长，这需要精准的药物动力学分析，以便根据个别患者的需求量身定制治疗方案。基因检测和生物标记识别技术的进步进一步推动了这一趋势，使得药物剂量和疗效评估更加精准。此外，生物製药和复杂药物的兴起也推动了对先进药物动力学分析的需求。这些治疗方法需要进行详细的研究，以了解其吸收、分布、代谢和排泄（ADME）特性。监管机构也正在实施严格的药物研发指南，迫使製药公司投资进行全面的药物动力学研究。此外，人工智慧（AI）和机器学习技术在药物动力学建模中的应用提高了预测的准确性和效率。这项技术进步使得药物研发过程更加快速有效率。最后，临床试验的全球化程度不断提高，企业寻求专业知识来应对不同的监管环境并优化跨地区的药物研发时间表，这进一步扩大了药物动力学服务的市场。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 吸收
    • 分配
    • 代谢
    • 排泄
  • 市场规模及预测：依产品划分
    • 软体
    • 分析设备
    • 消耗品
  • 市场规模及预测：依服务划分
    • 咨询
    • 生物分析
    • 资料管理
    • 临床试验
  • 市场规模及预测：依技术划分
    • LC-MS
    • HPLC
    • 气相层析层析法联用（GC-MS）
    • NMR
  • 市场规模及预测：依应用领域划分
    • 药物研发
    • 临床试验
    • 毒性测试
    • 生物等效性研究
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 合约研究机构
    • 学术机构
  • 市场规模及预测：依阶段划分
    • 临床前阶段
    • I期试验
    • II 期研究
    • 第三阶段
    • 售后

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Certara
  • Simulations Plus
  • Pharsight
  • Xeno Gesis
  • Pharmacelsus
  • Nuventra Pharma Sciences
  • Absorption Systems
  • Cyprotex
  • QPS
  • Inotiv
  • Pharmaron
  • Sygnature Discovery
  • TNO
  • Bioduro
  • Pharma Lex
  • KCAS Bioanalytical and Biomarker Services
  • Charles River Laboratories
  • Frontage Laboratories
  • Eurofins ADME BIOANALYSES
  • Wu Xi App Tec

第九章：关于我们

简介目录
Product Code: GIS26487

Pharmacokinetics Services Market is anticipated to expand from $1.6 billion in 2024 to $2.9 billion by 2034, growing at a CAGR of approximately 6%. The Pharmacokinetics Services Market encompasses analytical and consulting services that evaluate the absorption, distribution, metabolism, and excretion of drugs. These services are pivotal in drug development, ensuring safety and efficacy by providing critical data on drug interactions and dosage optimization. Increasing pharmaceutical R&D investments and the complexity of drug formulations are propelling market growth, emphasizing the need for advanced analytical techniques and regulatory compliance.

The Pharmacokinetics Services Market is experiencing robust growth, propelled by advancements in drug development and personalized medicine. The drug development segment is the top performer, driven by the increasing need for precise pharmacokinetic profiling in early-stage trials. Within this segment, bioanalytical services are paramount, ensuring accurate drug concentration measurement. The clinical pharmacokinetics sub-segment is also witnessing significant traction, as it provides critical insights into dosage optimization and therapeutic efficacy. The second highest performing segment is the contract research organizations (CROs), which are increasingly being leveraged for their expertise and cost-effectiveness. Within CROs, the small molecule pharmacokinetics services are gaining prominence, due to their established methodologies and demand in generic drug production. Biologics pharmacokinetics services are also emerging as a key area, reflecting the shift towards biologic drug development. The integration of advanced technologies, such as AI and machine learning, is enhancing data analysis capabilities, further driving market expansion.

Market Segmentation
TypeAbsorption, Distribution, Metabolism, Excretion
ProductSoftware, Analytical Instruments, Consumables
ServicesConsulting, Bioanalysis, Data Management, Clinical Trials
TechnologyLC-MS, HPLC, GC-MS, NMR
ApplicationDrug Development, Clinical Trials, Toxicology Testing, Bioequivalence Studies
End UserPharmaceutical Companies, Biotechnology Firms, Contract Research Organizations, Academic Institutions
StagePreclinical, Phase I, Phase II, Phase III, Post-Marketing

The Pharmacokinetics Services Market is witnessing a dynamic shift in market share, with emerging players challenging established entities. Pricing strategies are evolving, reflecting the increasing demand for personalized medicine and advanced drug development. Recent product launches emphasize innovative technologies and comprehensive service offerings, catering to a diverse clientele. Key regions are experiencing varied growth trajectories, driven by technological adoption and healthcare infrastructure improvements. As companies strive for competitive advantage, strategic collaborations and partnerships are becoming pivotal. Competition in the Pharmacokinetics Services Market is intensifying, with firms benchmarking against industry leaders to enhance service quality. Regulatory influences are significant, with stringent guidelines in North America and Europe shaping operational standards. Emerging markets in Asia-Pacific are rapidly aligning with global regulatory frameworks, offering new growth avenues. Market analysis reveals a trend towards integrated service models, combining pharmacokinetics with pharmacodynamics for holistic drug development solutions. The landscape is further enriched by advancements in bioanalytical techniques and personalized healthcare, promising robust future growth.

Geographical Overview:

The pharmacokinetics services market is witnessing notable growth across various regions, each with unique dynamics. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in drug development. The presence of key pharmaceutical companies further bolsters the region's market position. Europe follows closely with a strong emphasis on clinical research and regulatory frameworks, enhancing its market appeal. In the Asia Pacific region, the market is expanding rapidly, fueled by increasing R&D activities and a growing pharmaceutical industry. Countries like China and India are emerging as significant growth pockets, supported by favorable government initiatives and a rising focus on personalized medicine. Latin America and the Middle East & Africa present emerging opportunities, with increasing investments in healthcare infrastructure and drug discovery. Brazil in Latin America and the UAE in the Middle East are recognizing the importance of pharmacokinetics services in advancing medical research and improving therapeutic outcomes.

Global tariffs and geopolitical tensions are significantly influencing the Pharmacokinetics Services Market, particularly in East Asia. Japan and South Korea are navigating these challenges by enhancing their domestic research capabilities and fostering regional collaborations. China is accelerating its biopharmaceutical innovations and reducing dependency on Western services amidst export restrictions. Taiwan, while a pivotal player in the pharmaceutical supply chain, faces vulnerabilities due to its geopolitical positioning. The global market for pharmacokinetics services is experiencing robust growth, driven by increased demand for personalized medicine and advanced drug development. By 2035, the market is expected to evolve with greater emphasis on technological integration and regional partnerships. Middle East conflicts continue to disrupt global supply chains, indirectly affecting energy prices and operational costs across the pharmaceutical sector.

Key Trends and Drivers:

The pharmacokinetics services market is experiencing robust growth due to several pivotal trends and drivers. One significant trend is the increasing demand for personalized medicine, which necessitates precise pharmacokinetic profiling to tailor treatments to individual patient needs. This trend is further supported by advancements in genetic testing and biomarker identification, facilitating more accurate drug dosing and efficacy assessments. Additionally, the rise of biologics and complex pharmaceuticals is driving the need for sophisticated pharmacokinetic analysis. These therapies require detailed studies to understand their absorption, distribution, metabolism, and excretion (ADME) characteristics. Regulatory bodies are also enforcing stringent guidelines on drug development, compelling pharmaceutical companies to invest in comprehensive pharmacokinetic studies. Moreover, the integration of artificial intelligence and machine learning in pharmacokinetic modeling is enhancing predictive accuracy and efficiency. This technological advancement is allowing for more rapid and cost-effective drug development processes. Lastly, the globalization of clinical trials is expanding the market for pharmacokinetic services, as companies seek expertise to navigate diverse regulatory landscapes and optimize drug development timelines across different regions.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Absorption
    • 4.1.2 Distribution
    • 4.1.3 Metabolism
    • 4.1.4 Excretion
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software
    • 4.2.2 Analytical Instruments
    • 4.2.3 Consumables
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Bioanalysis
    • 4.3.3 Data Management
    • 4.3.4 Clinical Trials
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 LC-MS
    • 4.4.2 HPLC
    • 4.4.3 GC-MS
    • 4.4.4 NMR
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Drug Development
    • 4.5.2 Clinical Trials
    • 4.5.3 Toxicology Testing
    • 4.5.4 Bioequivalence Studies
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Firms
    • 4.6.3 Contract Research Organizations
    • 4.6.4 Academic Institutions
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Preclinical
    • 4.7.2 Phase I
    • 4.7.3 Phase II
    • 4.7.4 Phase III
    • 4.7.5 Post-Marketing

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Certara
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Simulations Plus
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Pharsight
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Xeno Gesis
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Pharmacelsus
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Nuventra Pharma Sciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Absorption Systems
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cyprotex
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 QPS
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Inotiv
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Pharmaron
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Sygnature Discovery
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 TNO
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bioduro
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Pharma Lex
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 KCAS Bioanalytical and Biomarker Services
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Charles River Laboratories
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Frontage Laboratories
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Eurofins ADME BIOANALYSES
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Wu Xi App Tec
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us